3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Hepatocellular
2
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Saline Solution
5
Sugammadex
2
Sodium Chloride
2
Sevoflurane
2
Propofol
2
Magnetic Resonance Spectroscopy
2
Levetiracetam
2
Fluorescein
2
Dexmedetomidine
2
Anesthesia, Inhalation
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
perampanel
1
pegvisomant
1
lorlatinib
1
gadoterate meglumine
1
gadobenic acid
1
dexketoprofen trometamol
1
clevidipine
1
Trastuzumab
1
Tramadol
1
Temozolomide
1
Positron-Emission Tomography
1
Phenylephrine
1
Patient-Specific Modeling
1
PF-05280014
1
PAVE protocol 2
1
Ontruzant
1
Ogivri
1
Octreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Brain Neoplasms
×
gadoterate meglumine
×
Clear all
NCT02034708
2016-12-30
REMIND
Guerbet
Phase 4
Completed
279 enrolled
9 charts